• Number of shares and voting rights of Innate Pharma as at July 17, 2019

    Источник: Nasdaq GlobeNewswire / 25 июл 2019 01:00:59   America/New_York

    NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT JULY 17, 2019

    Marseille, France, July 25, 2018, 7:00 AM CET

    Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter, Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) releases its total number of shares outstanding as well as its voting rights as at July 17, 2019:

    Total number of shares outstanding:64,135,464 ordinary shares
     6,931 Preferred Shares 2016
    7,581 Preferred Shares 2017
    Total number of theoretical voting rights (1):
    Total number of exercisable voting rights (2):
    64,143,045
    64,124,470

    (1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached (ordinary shares and Preferred Shares 2017), including shares whose voting rights have been suspended.

    (2) The total number of exercisable voting rights (or ”net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.

    About Innate Pharma:

    Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

    Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

    Innate has been a pioneer in the understanding of NK cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

    Based in Marseille, France, Innate Pharma is listed on Euronext Paris.

    Learn more about Innate Pharma at www.innate-pharma.com

    Information about Innate Pharma shares:

    ISIN code
    Ticker code
    LEI
    FR0010331421
    IPH
    9695002Y8420ZB8HJE29

    Disclaimer:

    This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Document de Reference prospectus filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website www.amf-france.org or on Innate Pharma’s website.

    This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

    For additional information, please contact:

    Investors

     

    Innate Pharma 

    Dr. Markus Metzger / Danielle Spangler /
    Jérôme Marino

    Tel.: +33 (0)4 30 30 30 30

    investors@innate-pharma.com

     
    International Media

     

    Consilium Strategic Communications

    Mary-Jane Elliott / Jessica Hodgson

    Tel.: +44 (0)20 3709 5700

    InnatePharma@consilium-comms.com
     French Media

     

    ATCG Press

    Marie Puvieux

    Mob: +33 (0)6 10 54 36 72
    innate-pharma@atcg-partners.com

    Attachment

Опубликовать